Regorafenib plus nivolumab in second-line hepatocellular carcinoma showed safety and survival signals in a Phase IIa trial.
Some Liver Cancer Patients Are Surviving Far Longer on a New Drug Combination
This Phase IIa trial evaluated regorafenib plus nivolumab as an add-on therapy in patients with hepatocellular carcinoma who had progressed …
A combination of regorafenib and nivolumab showed unexpectedly long survival in people with advanced liver cancer who had already exhausted …
Trifluridine/tipiracil plus irinotecan and bevacizumab in metastatic colorectal cancer resistant to prior chemotherapy
A New Second-Line Combo Shows Promise for Advanced Colon Cancer
This multicenter, single-arm, phase II trial evaluated biweekly trifluridine/tipiracil, irinotecan, and bevacizumab in 60 patients with meta…
For patients whose advanced colon cancer has stopped responding to initial chemo, a new drug combination is showing it can effectively fight…
Phase 1/2 trial shows RT + bevacizumab + olaptesed pegol extends PFS and OS in unmethylated GBM
New Drug Combo Slows Brain Cancer Growth
A Phase 1/2 expansion arm in six patients with newly-diagnosed, unmethylated GBM found that adding bevacizumab to radiotherapy and olaptesed…
Adding a second drug to stop blood vessel growth gives patients with brain cancer more time before the disease returns.
Guideline reviews perioperative immunotherapy for hepatocellular carcinoma after resection or ablation
A New Strategy Emerges to Stop Liver Cancer From Coming Back
A guideline reviews perioperative immunotherapy for hepatocellular carcinoma after resection or ablation. Adjuvant atezolizumab plus bevaciz…
Doctors are finding smarter ways to use the body’s own immune system around the time of surgery to give patients with liver cancer a better …
Case report and review of primary cervical melanoma shows inconsistent response to PD-1/PD-L1 inhibitors
Rare cervical melanoma cases show mixed results with immunotherapy and surgery
A case report of two patients with primary malignant melanoma of the cervix and a review of nine reported cases treated with PD-1/PD-L1 inhi…
Surgery alone fails for rare cervical melanoma, as 80% of patients progress on immunotherapy without chemotherapy or radiation.
Network meta-analysis finds similar overall survival for three HCC regimens
Three drugs show similar survival for unresectable liver cancer patients
A network meta-analysis of 11 studies in unresectable hepatocellular carcinoma found no statistically significant differences in overall sur…
Three drugs show similar survival for unresectable liver cancer patients, offering patients clearer choices without proving one option is de…
Nivolumab with chemotherapy and bevacizumab shows improved 4-year survival in advanced nonsquamous NSCLC
Nivolumab combination shows long-term survival benefit in advanced lung cancer trial
A Phase III randomized controlled trial of 550 patients with advanced nonsquamous NSCLC found nivolumab with carboplatin, paclitaxel, and be…
Adding nivolumab to standard lung cancer treatment helped patients live longer, with 34.7% surviving four years compared to 22.1% on placebo…
Intravitreal Anti-VEGF Shows Anatomic and Visual Gains in Irvine-Gass Syndrome Meta-Analysis
Can eye injections help people with Irvine-Gass syndrome see better?
A systematic review and meta-analysis of 343 eyes with Irvine-Gass syndrome found intravitreal anti-VEGF treatment was associated with a mea…
Eye injections for Irvine-Gass syndrome reduced swelling and improved vision in most patients, though doctors still need to prove these trea…
Meta-analysis: Anti-VEGF biosimilars show equivalent efficacy, safety to reference agents in nAMD
Can cheaper eye drugs work as well as expensive ones? A major review says yes for vision loss in older adults.
A meta-analysis of 17 RCTs (n=6694) found no clinically meaningful differences in BCVA improvement at 12 weeks (MD=-0.42, p=0.17) or endpoin…
Cheaper eye drug copies work just as well as expensive originals for treating vision loss in older adults, a major review confirms.
Phase II Study on SHR-8068 Injection in Colorectal Cancer Now Recruiting
Could a new treatment help fight colorectal cancer more effectively?
A Phase II trial is recruiting to assess SHR-8068 with Adebrelimab and Bevacizumab in colorectal cancer for pCR and PFS.
A new drug combo for colorectal cancer is being tested in 200 patients to see if it improves survival and tumor response.